# A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

> **NCT05201781** · PHASE4 · RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 295 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cilta-cel

## Key facts

- **NCT ID:** NCT05201781
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-09
- **Primary completion:** 2037-07-29
- **Final completion:** 2042-06-01
- **Target enrollment:** 295 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201781, "A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05201781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*